Research article Open Access
Like 0


The recent, and rapid, emergence of injection of the short-acting stimulant mephedrone (4-methylmethcathione) has resulted in concerns about increased infection risks among people who inject drugs (PWID). Data from the bio-behavioural surveillance of PWID in the United Kingdom were analysed to examine the impact of mephedrone injection on infections among PWID. During the year preceding the survey, 8.0% of PWID (163/2,047) had injected mephedrone. In multivariable analyses, those injecting mephedrone were younger, less likely to have injected opiates, and more likely to have injected cocaine or amphetamines, used needle/syringe programmes or sexual health clinics, been recruited in Wales and Northern Ireland or shared needles/syringes. There were no differences in sexual risks. Those injecting mephedrone more often had hepatitis C antibodies (adjusted odds ratio (AOR) = 1.51; 95% confidence interval (CI): 1.08–2.12), human immunodeficiency virus (AOR = 5.43; 95% CI: 1.90–15.5) and overdosed (AOR = 1.70; 95% CI: 1.12–2.57). There were no differences in the frequency of injecting site infections or prevalence of hepatitis B. The elevated levels of risk and infections are a concern considering its recent emergence. Mephedrone injection may currently be focused among higher-risk or more vulnerable groups. Targeted responses are needed to prevent an increase in harm.


Article metrics loading...

Loading full text...

Full text loading...



  1. Europol–European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) joint report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). Lisbon: EMCDDA; March 2010. Available from: www.emcdda.europa.eu/html.cfm/index132196EN.html
  2. Winstock AR, Ramsey JD. Legal highs and the challenges for policy makers. Addiction. 2010;105(10):1685-7. Available from:  https://doi.org/10.1111/j.1360-0443.2010.02934.x  PMID: 20840205 
  3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Responding to new psychoactive substances. Drugs in focus (ISSN 1681-5157). Lisbon: EMCDDA; 2011.
  4. Musshoff F, Hottmann L, Hess C, Madea B. ["Legal highs" from the German internet--"bath salt drugs" on the rise]. Arch Kriminol. 2013;232(3-4):91-103. German. PMID: 24358620 
  5. German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 2014;97(1):2-8. Available from:  https://doi.org/10.1016/j.lfs.2013.07.023  PMID: 23911668 
  6. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J Clin Psychopharmacol. 2012;32(5):710-4. Available from:  https://doi.org/10.1097/JCP.0b013e318266c70c  PMID: 22926609 
  7. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106(11):1991-6. Available from:  https://doi.org/10.1111/j.1360-0443.2011.03502.x  PMID: 21592252 
  8. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology (Berl). 2011;214(3):593-602. Available from:  https://doi.org/10.1007/s00213-010-2070-x  PMID: 21072502 
  9. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Injection of synthetic cathinones in Europe. Perspectives on Drugs series. Lisbon: EMCCDA; May 2014. Available from; www.emcdda.europa.eu/attachements.cfm/att_228233_EN_POD2014_Injection%20of%20synthetic%20cathinones.pdf
  10. Péterfi A, Tarján A, Horváth GC, Csesztregi T, Nyírády A. Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Anal. 2014;6(7-8):825-31. Available from:  https://doi.org/10.1002/dta.1625  PMID: 24692417 
  11. Oprea C, Ceausu E, Ruta S. Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania. Public Health. 2013;127(11):1048-50. Available from:  https://doi.org/10.1016/j.puhe.2013.08.018  PMID: 24239282 
  12. Kirby T, Thornber-Dunwell M. High-risk drug practices tighten grip on London gay scene. Lancet. 2013;381(9861):101-2. Available from:  https://doi.org/10.1016/S0140-6736(13)60032-X  PMID: 23320280 
  13. Peyrière H, Jacquet JM, Eiden C, Tuaillon E, Psomas C, Reynes J. Viral and bacterial risks associated with mephedrone abuse in HIV-infected men who have sex with men. AIDS. 2013;27(18):2971-2. Available from:  https://doi.org/10.1097/QAD.0000000000000029  PMID: 25119693 
  14. Kelly BC, Wells BE, Pawson M, Leclair A, Parsons JT, Golub SA. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013;32(6):588-93. Available from:  https://doi.org/10.1111/dar.12058  PMID: 23795887 
  15. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)–Europol 2008 annual report on the implementation of Council Decision 2005/387/JHA. Lisbon: EMCDDA; May 2009. Available from: www.emcdda.europa.eu/html.cfm/index132901EN.html
  16. Advisory Council on the Misuse of Drugs (ACMD). Consideration of cathinones. London: ACMD; 2010.
  17. A change to the misuse of drugs act 1971: control of mephedrone and other cathinone derivatives. London: Home Office; April 2010. Available from: http://webarchive.nationalarchives.gov.uk/20130125102358/http://www.homeoffice.gov.uk/about-us/corporate-publications-strategy/home-office-circulars/circulars-2010/010-2010/
  18. Daly M. ‘Drone strikes. Druglink. 2012;27(6):8-11. Available from: http://www.drugwise.org.uk/wp-content/uploads/Druglink-Nov-Dec-2012.pdf
  19. Van Hout MC, Bingham T. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy. 2012;23(3):188-97. Available from:  https://doi.org/10.1016/j.drugpo.2012.01.008  PMID: 22342322 
  20. Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, et al. HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS. 2005;19(11):1207-14. Available from:  https://doi.org/10.1097/01.aids.0000176222.71355.a1  PMID: 15990575 
  21. Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, et al. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol. 2009;170(3):352-60. Available from:  https://doi.org/10.1093/aje/kwp141  PMID: 19546152 
  22. Connell JA, Parry JV, Mortimer PP, Duncan J. Novel assay for the detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva and urine. J Med Virol. 1993;41(2):159-64. Available from:  https://doi.org/10.1002/jmv.1890410212  PMID: 8283178 
  23. Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol. 2003;71(1):49-55. Available from:  https://doi.org/10.1002/jmv.10463  PMID: 12858408 
  24. Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect. 2014;143(7):1398-407. PMID: 25119383 
  25. Judd A, Hickman M, Hope VD, Sutton AJ, Stimson GV, Ramsay ME, et al. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat. 2007;14(8):584-91. Available from:  https://doi.org/10.1111/j.1365-2893.2007.00844.x  PMID: 17650293 
  26. Powis B, Strang J, Griffiths P, Taylor C, Williamson S, Fountain J, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction. 1999;94(4):471-8. Available from:  https://doi.org/10.1046/j.1360-0443.1999.9444712.x  PMID: 10605843 
  27. Business as usual? A status report on new psychoactive substsances (NPS) and 'club drugs' in the UK. London: Drugscope; 2014. Available from: http://www.drugwise.org.uk/wp-content/uploads/businessasusual.pdf
  28. UK Focal Pont at Public Health England. United Kingdom drug situation: Annual report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2013. Davies C, Murray R, eds. London: Public Health England; October 2013. Available from: www.nta.nhs.uk/uploads/24780focalpointreport2013.pdf
  29. Hay G, Rael dos Santos A, Worsley J. Estimates of the prevalence of opiate use and/or crack cocaine use, 2011/12: Sweep 8 report. Liverpool: John Moores University; April 2014. Available from: www.nta.nhs.uk/facts-prevalence.aspx
  30. UK Focal Pont at Public Health England. United Kingdom drug situation: Annual Report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2009. Davies C, English L, Lodwick A, McVeigh J, Bellis, M, eds. London: Public Health England; October 2009. Available from: http://www.nta.nhs.uk/uploads/2009.pdf
  31. Public Health England, Health Protection Scotland, Public Health Wales, and Public Health Agency Northern Ireland. Shooting Up: Infections among people who inject drugs in the United Kingdom 2013. London: Public Health England, November 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/370707/Shooting_Up_2014.pdf
  32. Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. outbreak control team. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Euro Surveill. 2015;20(40):30036. Available from:  https://doi.org/10.2807/1560-7917.ES.2015.20.40.30036  PMID: 26537764 
  33. Gilbart VL, Simms I, Gobin M, Oliver I, Hughes G. High-risk drug practices in men who have sex with men. Lancet. 2013;381(9875):1358-9. Available from:  https://doi.org/10.1016/S0140-6736(13)60882-X  PMID: 23601946 
  34. Simms I, Gilbart VL, Byrne L, Jenkins C, Adak GK, Hughes G, et al. Identification of verocytotoxin-producing Escherichia coli O117:H7 in men who have sex with men, England, November 2013 to August 2014. Euro Surveill. 2014;19(43):20946. Available from:  https://doi.org/10.2807/1560-7917.ES2014.19.43.20946  PMID: 25375900 
  35. Bourne A, Reid D, Hickson F, Torres Rueda S, Weatherburn P. The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark & Lewisham. London: Sigma Research, London School of Hygiene and Tropical Medicine; 2014.
  36. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34-52. Available from:  https://doi.org/10.1016/j.drugpo.2013.07.001  PMID: 23973009 
  37. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health and devolved administrations, 2007. Available from: www.nta.nhs.uk/uploads/clinical_guidelines_2007.pdf
  38. European Centre for Disease Prevention and Control (ECDC). Mapping of HIV/STI behavioural surveillance in Europe. ECDC Technical Report. Stockholm: ECDC; September 2009. Available from: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_Mapping_of_HIV_STI_Behavioural_Surveillance_in_Europe.pdf
  39. Topp L, Iversen J, Wand H, Day C, Kaldor J, Maher LCollaboration of Australian Needle Syringe Programs. Representativeness of injecting drug users who participate in HIV surveillance: results from Australia’s Needle and Syringe Program Survey. J Acquir Immune Defic Syndr. 2008;47(5):632-8. Available from:  https://doi.org/10.1097/QAI.0b013e31816a1d68  PMID: 18491422 
  40. Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat. 2007;14(9):645-52. Available from:  https://doi.org/10.1111/j.1365-2893.2007.00855.x  PMID: 17697017 
  41. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993;88(4):517-26. Available from:  https://doi.org/10.1111/j.1360-0443.1993.tb02058.x  PMID: 8485429 
  42. De Irala J, Bigelow C, McCusker J, Hindin R, Zheng L. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol. 1996;143(7):725-32. Available from:  https://doi.org/10.1093/oxfordjournals.aje.a008806  PMID: 8651235 
  43. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report: trends and developments. Lisbon: EMCDDA; June 2015. Available from: www.emcdda.europa.eu/publications/edr/trends-developments/2015

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error